Saturday 17 October 2026
Export TAK’s income statement to Excel — free account
Takeda Pharmaceutical Co.
TAK Healthcare Drug Manufacturers Specialty & Generic
Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025. In the quarter to June 2026, revenue grew 1.71%, EPS fell 4.35%, free cash flow fell 95.6% and total debt fell 2.58%, each against the same quarter a year earlier.
19.67
0.22
+1.13%
Follow TAK
| Jun '26 | Dec '25 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
24.12 | — | — | 22.92 |
+8 more quarters Free account |
P/S ratio |
1.69 | — | — | 1.62 | |
P/FCF ratio |
6.83 | — | — | 7.65 | |
P/Operating CF |
63.00 | — | — | 32.55 | |
P/B ratio |
1.06 | — | — | 1.02 | |
Price to Tangible BV |
0.00 | — | — | 0.00 | |
EV/Sales |
2.62 | — | — | 2.56 | |
EV/EBITDA |
9.41 | — | — | 9.59 | |
EV/Operating CF |
7.05 | — | — | 7.64 | |
EV/FCF |
10.57 | — | — | 12.11 | |
Quick Ratio |
0.54 | 0.58 | 0.67 | 0.51 | |
Current Ratio |
1.14 | 1.19 | 1.37 | 1.16 | |
Net Debt/EBITDA |
12.11 | 0.00 | 0.00 | 11.16 | |
Debt/Assets |
31.54% | 31.50% | 32.10% | 32.17% | |
Debt/Equity |
0.65 | 0.63 | 0.65 | 0.66 | |
Asset Turnover |
0.30 | 0.00 | 0.00 | 0.30 | |
Operating CF/Net income |
1.13 | 0.00 | 0.00 | 1.73 | |
Capex/Depreciation |
(0.63) | (0.62) | (0.28) | (0.38) | |
Interest Coverage |
3.15 | — | — | 1.72 | |
Research and Development Expense of Revenue |
13.72% | — | — | 13.00% | |
Selling, General and Administrative Expense of Revenue |
23.49% | — | — | 23.12% | |
Intangible Assets out of Total Assets |
0.59 | 0.60 | 0.60 | 0.62 | |
Share Based Compensation of Revenue |
1.49% | 0.00% | 0.00% | 1.49% | |
Graham Net Nets |
(0.62) | — | — | (0.66) | |
Graham Number |
15.01 | — | — | 15.16 | |
Earnings Yield |
4.15% | — | — | 4.36% | |
Free Cash Flow Yield |
14.65% | — | — | 13.07% | |
Revenue per Share |
2.43 | — | — | 2.44 | |
Operating CF per Share |
0.25 | 0.00 | 0.00 | 0.48 | |
Capex per Share |
(0.20) | 0.00 | 0.00 | (0.15) | |
Free Cash Flow per Share |
0.05 | 0.00 | 0.00 | 0.32 | |
Cash per Share |
1.05 | 0.00 | 0.00 | 0.92 | |
Shareholders Equity per Share |
15.07 | 0.00 | 0.00 | 15.14 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
15.07 | 0.00 | 0.00 | 15.14 | |
Free Cash Flow |
160.54 | 4,049.74 | 2,198.07 | 1,012.51 | |
Working Capital |
2,430.05 | 3,290.66 | 5,310.57 | 2,370.40 | |
Capital Expenditures |
(643.48) | (2,235.13) | (352.34) | (473.91) | |
Net Current Asset Value |
(31,210.98) | (30,213.59) | (30,042.33) | (31,914.13) | |
EV/EBIT |
22.54 | — | — | 26.18 | |
Capex to Sales |
0.08 | 0.00 | 0.00 | 0.06 | |
Price to Operating Income |
14.55 | — | — | 16.54 | |
| Other line items | |||||
Average Receivables |
5,437.55 | 4,878.78 | 4,859.18 | 4,751.14 | |
Average Payables |
2,925.97 | 2,904.35 | 2,992.97 | 3,342.46 | |
Average Inventory |
8,672.07 | 8,614.92 | 8,503.82 | 8,454.38 | |
Average Assets |
99,191.89 | 98,898.05 | 101,127.62 | 100,441.00 | |
Average Common Equity |
48,293.79 | 48,030.65 | 49,205.30 | 48,783.64 |
Columns are period end dates